Navigation path

Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Virbagen Omega   
Auth. number : EU/2/01/030
Active substance : recombinant omega interferon of feline origin
ATC: Anatomical main group: QL - Antineoplastic and immunomodulating agents
Therapeutic subgroup: QL03 - Immunostimulants
Pharmacological subgroup: QL03A - Immunostimulants
Chemical subgroup: QL03AB - interferons
Chemical substance: QL03AB - interferons
(See WHO ATCvet Index)
Indication: Dogs :
Reduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.
Cats :
Treatment of cats infected with FeLV and/or FIV, in non-terminal clinical stages, from the age of 9 weeks. In a field study conducted, it was observed that there was :
- a reduction of clinical signs during the symptomatic phase (4 months)
- a reduction of mortality :
• in anaemic cats, mortality rate of about 60% at 4, 6, 9 and 12 months was reduced by approximately 30% following treatment with interferon.
• in non-anaemic cats, mortality rate of 50 % in cats infected by FeLV was reduced by 20% following treatment with interferon. In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.
Marketing Authorisation Holder: VIRBAC S.A.
1ère Avenue - 2065 m - L.I.D., 06516 Carros CEDEX, France
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
08/11/2001 Centralised - Authorisation EMEA/V/C/61 (2001)3484 of 06/11/2001
02/08/2004 Centralised - Variation EMEA/V/C/61/X/1 (2004)2935 of 29/07/2004
20/12/2004 Centralised - Notification EMEA/V/C/61/N/2
Updated with Decision(2005)3351 of 26/08/2005
07/02/2005 Centralised - Variation EMEA/V/C/61/IA/3
Updated with Decision(2005)3351 of 26/08/2005
31/08/2005 Centralised - Variation EMEA/V/C/61/IA/3 (2005)3351 of 26/08/2005
22/11/2006 Centralised - Renewal EMEA/V/C/61/R/4 (2006)5669 of 20/11/2006
21/04/2008 Centralised - Variation EMEA/V/C/61/II/5 (2008)1609 of 17/04/2008
20/05/2011 Centralised - Variation EMEA/V/C/61/IA/6
Updated with Decision(2011)5824 of 05/08/2011
10/08/2011 Centralised - Variation (2011)5824 of 05/08/2011
21/12/2016 Centralised - Variation EMEA/V/C/61/IG/724
Updated with Decision(2018)232 of 12/01/2018
16/01/2018 Centralised - Yearly update (2018)232 of 12/01/2018